UNSPSC 51442407: Iobenguane sulfate

This classfication denotes an iodinated contrast dye with the molecular formula 2C8H10IN3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8I0922465, chemically known as guanidine, n-((3-iodophenyl)methyl)-, sulfate (2:1), but more generally known as iobenguane sulfate, which bears U.S. National Institutes of Health Compound Identifier 2759362. European Medicines Agency schedules iobenguane sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32630.

Most nations, for tariff purposes, schedule iobenguane sulfate under HS 28444030. SMILES: C1CC(CC(C1)I)CNC(=N)N.C1CC(CC(C1)I)CNC(=N)N.OS(=O)(=O)O.

UNSPSC 51442407 Iobenguane sulfate, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The two most recent opportunities posted under this code—a Broward County Aviation Department RFI for Rapiscan X-ray system maintenance services and a Pasco County RFQ for copper sulfate chemicals—are unrelated to iobenguane sulfate, a diagnostic radiopharmaceutical used in medical imaging. State and local governments do not appear to be actively procuring iobenguane sulfate or related nuclear medicine products through this UNSPSC classification in current market activity.

The geographic and issuing-body signals offer no actionable pattern. The two posted opportunities originate from Florida county-level agencies (Broward County and Pasco County) and address unrelated commodities entirely outside pharmaceutical supply chains. No state health departments, hospital systems, or other medical procurement bodies appear in the recent record under this code. The mismatch between the code's intended scope and the actual opportunities posted suggests either minimal demand for iobenguane sulfate through state and local channels or systematic miscoding of opportunities by issuing offices. Firms evaluating this code should verify whether their target customers classify radiopharmaceuticals under alternative UNSPSC families or manage such procurements through federal or hospital-specific acquisition channels rather than general-market state and local bids.